Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 11 years
- Director since
- 2023
11 years of board service in total across 4 boards, counting each seat separately. Longest: Stepan Company, 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Avita Medical Inc. June 3, 202678.4%
-
Avita Medical Inc. June 4, 202582.5%
-
Avita Medical Inc. June 5, 202483.7%
-
Stepan Company April 30, 202499.0%
-
AngioDynamics Inc. November 14, 202393.6%
-
Avita Medical Inc. June 6, 202388.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 15, 2026 | AngioDynamics Inc. | Grant or award | +11,887 | — | — |
| May 8, 2026 | Stepan Company | Grant or award | +2,566 | $52.61 | $134,997 |
| Jan 20, 2026 | Avita Medical Inc. | Grant or award | +22,214 | — | — |
| Jul 16, 2025 | AngioDynamics Inc. | Grant or award | +17,675 | — | — |
| May 12, 2025 | Stepan Company | Grant or award | +2,500 | $54.26 | $135,650 |
| Jan 21, 2025 | Avita Medical Inc. | Grant or award | +10,022 | — | — |
| Jul 17, 2024 | AngioDynamics Inc. | Grant or award | +20,541 | — | — |
| Jun 5, 2024 | Avita Medical Inc. | Grant or award | +9,200 | — | — |
| May 10, 2024 | Stepan Company | Grant or award | +1,396 | $89.53 | $124,984 |
| Jul 19, 2023 | AngioDynamics Inc. | Grant or award | +17,041 | — | — |
| Jun 6, 2023 | Avita Medical Inc. | Grant or award | +6,175 | — | — |
| Apr 25, 2023 | Stepan Company | Grant or award | +1,325 | $94.32 | $124,974 |
Questions about Jan Stern Reed
What boards is Jan Stern Reed on?
Jan Stern Reed sits on the boards of AngioDynamics Inc., Avita Medical Inc., GMR Solutions Inc. and Stepan Company.
How long has Jan Stern Reed served on boards?
Our records show at least 11 years of board service across 4 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.